Government-Owned Inventions; Availability for Licensing, 16757 [2022-06174]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 57 / Thursday, March 24, 2022 / Notices
certification to ORI at the conclusion of
the Supervision Period that his
participation was not proposed on a
research project for which an
application for PHS support was
submitted and that he has not
participated in any capacity in PHSsupported research.
(5) During the Exclusion and
Supervision Periods, Respondent will
exclude himself voluntarily from
serving in any advisory or consultant
capacity to PHS including, but not
limited to, service on any PHS advisory
committee, board, and/or peer review
committee.
Dated: March 21, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity,
Office of the Assistant Secretary for Health.
[FR Doc. 2022–06246 Filed 3–23–22; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Peter Tung at 240–669–5483 or
peter.tung@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows:
VerDate Sep<11>2014
17:39 Mar 23, 2022
Jkt 256001
16757
Novel Compositions of Matter
Comprising Stabilized Coronavirus
Antigens and Their Use
• Computational method of designing
vaccine antigens.
Description of Technology
• Pre-clinical testing of the novel
immunogens in non-human primates.
Inventors: Dr. Niraj Tolia and Dr.
Thayne Dickey, both of NIAID.
Publications: ‘‘Design of the SARSCoV–2 RBD vaccine antigen improves
neutralizing antibody response’’,
https://doi.org/10.1101/2021.05.09.
443238.
Intellectual Property: HHS Reference
No. E–045–2021–0–US–01—U.S.
Provisional Application No. 63/200,194,
filed February 18, 2021; PCT/US2022/
070744, filed February 1, 2022
Licensing Contact: To license this
technology, please contact Peter Tung at
240–669–5483 or peter.tung@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the invention. For
collaboration opportunities, please
contact Peter Tung at 240–669–5483;
peter.tung@nih.gov.
Using a computational design
methodology, SARS-CoV–2 spike
proteins containing engineered amino
acid changes to the receptor binding
domain (RBD) were designed. These
engineered spike proteins improved the
immune response upon immunization
of animals. An engineered RBD was also
expressed at greater yield, had increased
temperature stability, and improved the
immune response upon immunization
of animals. Specifically, the disclosed
RBD designs can be produced
approximately 7 times more efficiently
than the native sequence, facilitating
vaccine manufacturing on a global scale.
The disclosed designs also have up to
10 °C higher thermal stability than the
native sequence, suggesting enhanced
stability during storage and when in the
body. Finally, immunization of animals
with the disclosed antigens produces up
to 10-fold higher levels of blocking
antibodies than the native sequence and
30-fold higher levels of pseudoviral
neutralizing antibodies. An additional
RBD protein has been engineered to
eliminate the need for glycosylation,
facilitating production and singlecomponent nanoparticle display of the
antigen. The engineered receptor
binding domain (RBD) and spike protein
antigens produce significant
improvements in pre-clinical animal
models and may be used to develop
improved coronavirus vaccines.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
• Novel SARS-CoV–2 vaccine.
• Improved SARS-CoV–2 diagnostics
using stabilized antigens.
• Method of designing vaccine
candidates or stabilized antigens by
computational. optimization of amino
acid identity, followed by additional
sequence comparison and selection
(Stabilizer for Protein Expression and
Epitope Design (SPEEDesign)).
Competitive Advantages
• Novel SARS-CoV–2 spike vaccine
with improved breadth and duration of
protection.
• Novel RBD monomer and
nanoparticle designs that are more
immunogenic and stable than the
naturally occurring RBD sequence.
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Development Stage
Dated: March 17, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2022–06174 Filed 3–23–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Antimicrobial Resistant Infections.
Date: April 19, 2022.
E:\FR\FM\24MRN1.SGM
24MRN1
]]>Agencies
[Federal Register Volume 87, Number 57 (Thursday, March 24, 2022)]
[Notices]
[Page 16757]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-06174]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Peter Tung at 240-669-5483 or
[email protected]. Licensing information and copies of the patent
applications listed below may be obtained by communicating with the
indicated licensing contact at the Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows:
Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens
and Their Use
Description of Technology
Using a computational design methodology, SARS-CoV-2 spike proteins
containing engineered amino acid changes to the receptor binding domain
(RBD) were designed. These engineered spike proteins improved the
immune response upon immunization of animals. An engineered RBD was
also expressed at greater yield, had increased temperature stability,
and improved the immune response upon immunization of animals.
Specifically, the disclosed RBD designs can be produced approximately 7
times more efficiently than the native sequence, facilitating vaccine
manufacturing on a global scale. The disclosed designs also have up to
10 [deg]C higher thermal stability than the native sequence, suggesting
enhanced stability during storage and when in the body. Finally,
immunization of animals with the disclosed antigens produces up to 10-
fold higher levels of blocking antibodies than the native sequence and
30-fold higher levels of pseudoviral neutralizing antibodies. An
additional RBD protein has been engineered to eliminate the need for
glycosylation, facilitating production and single-component
nanoparticle display of the antigen. The engineered receptor binding
domain (RBD) and spike protein antigens produce significant
improvements in pre-clinical animal models and may be used to develop
improved coronavirus vaccines.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
Novel SARS-CoV-2 vaccine.
Improved SARS-CoV-2 diagnostics using stabilized antigens.
Method of designing vaccine candidates or stabilized
antigens by computational. optimization of amino acid identity,
followed by additional sequence comparison and selection (Stabilizer
for Protein Expression and Epitope Design (SPEEDesign)).
Competitive Advantages
Novel SARS-CoV-2 spike vaccine with improved breadth and
duration of protection.
Novel RBD monomer and nanoparticle designs that are more
immunogenic and stable than the naturally occurring RBD sequence.
Computational method of designing vaccine antigens.
Development Stage
Pre-clinical testing of the novel immunogens in non-human
primates.
Inventors: Dr. Niraj Tolia and Dr. Thayne Dickey, both of NIAID.
Publications: ``Design of the SARS-CoV-2 RBD vaccine antigen
improves neutralizing antibody response'', https://doi.org/10.1101/2021.05.09.443238.
Intellectual Property: HHS Reference No. E-045-2021-0-US-01--U.S.
Provisional Application No. 63/200,194, filed February 18, 2021; PCT/
US2022/070744, filed February 1, 2022
Licensing Contact: To license this technology, please contact Peter
Tung at 240-669-5483 or [email protected].
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize the invention. For collaboration
opportunities, please contact Peter Tung at 240-669-5483;
[email protected].
Dated: March 17, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-06174 Filed 3-23-22; 8:45 am]
BILLING CODE 4140-01-P
